Xenon Pharmaceuticals Inc. (XENE) insider trading.
In Q3 2026, insiders at Xenon Pharmaceuticals Inc. reported 4 non-derivative transactions on 3 Forms 3, 4 and 5: 0 open-market purchases and 3 sales worth $1.1M.
- Transactions
- 4
- Purchases (P)
- 0
- Sales (S)
- 3
- Net shares, P minus S
- -17,068
- Insiders
- 3
- Last filed
- 2026-09-03
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Kenney Christopher John | Officer · Chief Medical Officer | 2 | 0 | 2 |
| Svoronos Dawn | Director | 1 | 0 | 0 |
| Gannon Steven | Director | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-01 | Svoronos Dawn | M (A) | 5,144 | $8.15 | 31,373 | Form 4 |
| 2026-08-28 | Kenney Christopher John | S (D) | 6,368 | $60.17 | 702 | Form 4 |
| 2026-08-28 | Kenney Christopher John | S (D) | 700 | $60.98 | 2 | Form 4 |
| 2026-08-11 | Gannon Steven | S (D) | 10,000 | $64.06 | 1,870 | Form 4 |
Transaction codes in this quarter
Get XENE insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1582313&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · XENE company page · Xenon Pharmaceuticals Inc. on SEC.gov
Questions
Are insiders buying or selling Xenon Pharmaceuticals Inc. (XENE)?
In Q3 2026, insiders at Xenon Pharmaceuticals Inc. reported 4 non-derivative transactions on 3 Forms 3, 4 and 5: 0 open-market purchases and 3 sales worth $1.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Xenon Pharmaceuticals Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/xene.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.